Corient Private Wealth
CNTX icon

Corient Private Wealth’s Context Therapeutics CNTX Stock Holding History

Corient Private Wealth’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.5K Sell
26,534
-3,634
-12% -$8.49K ﹤0.01% 2734
2025
Q4 		$44.3K Buy
+30,168
New +$35.2K ﹤0.01% 2680

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Corient Private Wealth's CNTX Position: Q1 2026 in Review

Corient Private Wealth reduced its Context Therapeutics (CNTX) stake by 12% in Q1 2026, selling an estimated $8.49K and leaving 26,534 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2734.

Corient Private Wealth first reported a position in CNTX in Q4 2025 and has held it in 2 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Corient Private Wealth held 26,534 shares of Context Therapeutics worth $69.5K as of Q1 2026.
  • Corient Private Wealth sold 3,634 Context Therapeutics shares in Q1 2026, an estimated $8.49K.
  • Context Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2734 holding.
  • Corient Private Wealth first reported a position in Context Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.